Intestinal Immunity in Neurologic Disease
NCT06329453 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-04-11
Summary
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
Conditions
- Multiple Sclerosis
- Parkinson Disease
- REM Sleep Behavior Disorder
Interventions
- PROCEDURE
-
Colon Tissue Biopsy
Colonoscopy and colon tissue biopsy.
Sponsors & Collaborators
-
Yale University
lead OTHER
Principal Investigators
-
Erin Longbrake · Yale University
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-08-02
- Primary Completion
- 2027-08-31
- Completion
- 2027-08-31
Countries
- United States
Study Locations
More Related Trials
-
Autoimmune Gastrointestinal Dysmotility: Symptoms, Pathogenesis and Treatment
NCT04859829 ·Status: TERMINATED
-
T Lymphocyte Subsets in Ulcerative Colitis
NCT06352515 ·Status: NOT_YET_RECRUITING
-
Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
NCT03278912 ·Status: WITHDRAWN
-
Pathogenic Study of Adult Immune Enteropathies
NCT04280510 ·Status: RECRUITING
-
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT01988961 ·Status: COMPLETED ·Phase: PHASE2
-
Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)
NCT02516384 ·Status: COMPLETED ·Phase: PHASE1
-
Collection of Specimens for Study of Inflammatory Bowel Disease
NCT00086554 ·Status: COMPLETED
-
Immunological Characteristics of Patients With PID and IBD
NCT03148028 ·Status: UNKNOWN
-
In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis
NCT02852850 ·Status: UNKNOWN
-
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
NCT02092285 ·Status: COMPLETED ·Phase: PHASE4
-
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
NCT00207688 ·Status: COMPLETED
-
Local and Systemic Immunoprofiling of Patients Diagnosed With Ulcerative Colitis
NCT05680883 ·Status: UNKNOWN
-
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
NCT04031469 ·Status: SUSPENDED
-
Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction
NCT02729233 ·Status: WITHDRAWN ·Phase: NA
-
Immunological Profiles in Inflammatory Bowel Disease
NCT03366090 ·Status: UNKNOWN
-
Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis
NCT03259659 ·Status: TERMINATED
-
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis
NCT00096655 ·Status: COMPLETED ·Phase: PHASE3
-
Brain-Gut Interactions in Crohn's Disease
NCT02108938 ·Status: COMPLETED
-
Immune Ablation and Stem Cell Support for Crohn's Disease
NCT00179842 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
NCT00656890 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease
NCT00269854 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Mucosal Innate Immune Activation in Chronic Intestinal Disorders
NCT03529318 ·Status: WITHDRAWN
-
The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis
NCT02389075 ·Status: ACTIVE_NOT_RECRUITING
-
Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine
NCT05584735 ·Status: COMPLETED
-
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
NCT06619990 ·Status: RECRUITING ·Phase: PHASE1/PHASE2